Friedmann P S, White S I, Parker S, Moss C, Matthews J N
Dermatology Department, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
Clin Exp Immunol. 1989 Apr;76(1):68-72.
People receiving therapy with either 8-methoxypsoralen plus long wavelength ultraviolet radiation (PUVA) or medium wavelength ultraviolet radiation (UVB) have been studied to see whether their unresponsiveness to the contact sensitizer dinitrochlorobenzene (DNCB) is a form of immunological tolerance. It was confirmed that both PUVA and UVB therapy impair sensitization by DNCB:4/13 PUVA-treated and 9/29 UVB-treated psoriatic subjects became sensitized by a dose of DNCB which sensitizes 100% of untreated patients. Subjects unsuccessfully sensitized during PUVA therapy could subsequently be sensitized perfectly normally. Subjects unsuccessfully sensitized during UVB therapy showed slight impairment of subsequent sensitization which was not statistically significant, and which was probably a persistent effect of UVB exposure. In conclusion, the temporary unresponsiveness seen in human subjects exposed to antigens during PUVA or UVB therapy is not due to immunological tolerance.
对接受8-甲氧基补骨脂素加长波紫外线辐射（PUVA）或中波紫外线辐射（UVB）治疗的患者进行了研究，以确定他们对接触性致敏剂二硝基氯苯（DNCB）无反应是否属于一种免疫耐受形式。已证实PUVA和UVB治疗均会损害DNCB致敏：13名接受PUVA治疗的银屑病患者中有4名、29名接受UVB治疗的患者中有9名，通过一定剂量的DNCB致敏成功，而该剂量可使100%的未治疗患者致敏。在PUVA治疗期间致敏失败的患者随后可完全正常地致敏。在UVB治疗期间致敏失败的患者随后的致敏略有受损，但无统计学意义，这可能是UVB照射的持续影响。总之，在接受PUVA或UVB治疗期间接触抗原的人体受试者中观察到的暂时无反应并非由于免疫耐受。
